Form 4: Silence Therapeutics Director Acquires Shares in Latest Transaction

Director Richard Ian Griffiths reports acquisition of Silence Therapeutics plc shares through Cream Capital Limited.

Summary

• Richard Ian Griffiths, a director of Silence Therapeutics plc, reported a transaction on March 5, 2025.
• He acquired 22,632 American Depositary Shares (ADS) at a price of $4.50.
• These ADS are held indirectly through Cream Capital Limited, where Mr. Griffiths is a director and controlling shareholder.
• Each ADS is immediately convertible into three ordinary shares.
• Following the transaction, Mr. Griffiths beneficially owns 9,561,299 ordinary shares indirectly through Cream Capital Limited.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding a director's share acquisition. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.

Management Comments

• Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

Industry Context

This filing reflects insider activity, which is closely monitored by investors for signals about management's confidence in the company's prospects. It is common for directors to hold shares, and this transaction represents an increase in Griffiths' holdings.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder confidence, as it signals that a director is increasing their investment in the company.

Key Dates